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1. Introduction
  Malaria is one of the oldest and important parasitic 
disease in humans with more than 3 billion people at risk 
of Plasmodium falciparum (P. falciparum) infection. It is 
estimated that the disease afflicts 515 million cases and 
kills 1.5-2.7 million people each year, most of these are 
children under 5 years old in sub-Saharan Africa[1,2]. P. 
falciparum, the most dangerous of the four human malaria 
parasites [P. falciparum, Plasmodium vivax (P. vivax), 
Plasmodium ovalae (P. ovalae), Plasmodium malariae (P. 
malariae)], is responsible for the majority of deaths. The 
deaths in young children may due to (1) overwhelming acute 
infection, frequently presenting as coma (cerebral malaria), 
respiratory distress, hypoglycemia, resulting to a quick 
death in a young child; (2) chronic and repeated infections, 
resulting to severe anemia which substantially increase the 
risk of death; (3) infection in pregnant women, resulting in 
low birth weight and the major risk factor for death in the 
first month of life[3].
  For decades, efforts to eradicate malaria have been met 
with the emergence of resistance to most of antimalarial 
drugs such as chloroquine, sulfadoxine-pyrimethamine, 
amodiaquine and mefloquine; insecticides and other 
ecological concerns[4,5]. Since malaria chemotherapy has 
relied on a limited number of drugs, the acquisition and 
spread of drug resistance has led to an increase in morbidity 
and mortality rates in malaria endemic countries in recent 
years (Figure 1)[6]. In view of this situation, the World 
Health Organization (WHO) has recommended the use of 
artemisinin-based combination therapy (ACT) as the first-
line drug for the treatment of uncomplicated P. falciparum 
malaria since 2001[7]. Moreover with the post-genomic 
era of the falciparum malaria parasite there has also been 
renewed efforts to search for candidate drug targets suitable 
for chemotherapy (Table 1) as well as understanding of 
molecular resistance mechanism of existing drugs for new 
antimalarial development[4,8-15]. There are more than 20 
new drug targets, mostly active small molecule inhibitors, 
that are currently under investigation[4,8-10]. By using in 
silico analysis and high throughput screening of more than 
4 million compounds, nearly 20 thousands of them are 
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identified as antimalarial lead compounds[11,13-15].
  This article will focus on artemisinins, known as the 
world’s best drug to eradicate malaria, its mechanism of 
action and ACT. In addition, resistance/tolerance of the 
falciparum parasite to artemisinin as observed in both in 
vitro and human patients at the Thai-Cambodian border will 
be discussed.
Certified malaria-free
and lor no ongoing
local transmission






Figure 1. Epidemiology of malaria.
Based on WHO 2008, five areas are classified for global malaria 
control program: malaria-free countries, prevention of reintroduction 
area, elimination zone, pre-elimination zone and control area[6].
2. Artemisinin structure and mechanism of action
  Artemisinin (qinghaosu), the active antimalarial principle 
of the Chinese herb, qinghao or huang hua hao (Artemisia 
annua L.), has been used for malaria therapy in China for 
over 1 000 years[16]. The drug was isolated and chemically 
characterized in 1971, and was distributed to the rest of the 
world in 1979. Its structure is a 15-carbon sesquiterpine 
lactone bearing a 6-lactone and an endoperoxide 
group (Figure 2). To increase solubility of artemisinin, 
arteether and artemether are synthesized as lipid soluble; 
artesunate and artelinic acid as water soluble derivatives. 
Dihydroartemisinin is an active metabolite of the drugs[17]. 
Loss of the endoperoxide linkage yields an inactive 














Figure 2. Chemical structures of artemisinin and derivatives.
  Artemisinin derivatives are the most rapid acting and 
efficacious antimalarial drugs currently available[17]. The 
artemisinins have antimalarial activity against asynchronous 
P. falciparum in vitro (using the multidrug resistant parasite 
K1 strain) with 50% inhibitory concentration (IC50) values 
of 0.6-1.1 nM, (ring-stage parasites  are more susceptible 
to artemisinin (IC50= 0.3 nM) than trophozoite and schizont 
stages (IC50=5.0 nM)[18]. The compounds are also effective for 
P. falciparum sexual gametocyte at early or young stages 
and for P. vivax asexual blood stages, but have no killing 
effect on the pre-erythrocytic parasite development or the 
latent hypnozoite stages of  P. vivax and P. ovalae. 
  Acute toxicity of artemisinins is higher than chloroquine 
and quinine. In many animals and humans so far examined, 
artemisinins exhibit their toxicities through temporarily 
suppression on the central nervous system, liver function, 
reticulocyte reduction, bone marrow hematopoietic cells, 
embryonic primitive erythroblasts, cardiovascular and 
appendicular skeletal malformation in embryos. These 
raises potential consequences for use in women, especially 
in the first trimester[17,19]. However, despite these risks, 
artemisinins have also passed safety tests, proven to be 
well tolerated and considered as safe drugs. They also 
have potential roles in the treatment of trypanosomiasis, 
schistosomiasis, fascioliasis, and also human cancer[17].
  The half-life of artemisinins is about 1 hour after oral 
or parenteral administration in both healthy humans and 
in patients with falciparum malaria. When measured 
in the blood, the drugs and their major metabolite, 
dihydroartemisinin, peaks approximately 1-2 hours after 
administration with concentrations of about 10-30 毺M (2.4-
4.0 mg/kg). Subsequently, the drugs are then eliminated 
to inactive metabolites by human cytochrome P2B6 
glucuronidation[17]. 
  The mechanism of the antimalarial action of artemisinins 
is not well understood. This remains a topic of considerable 
debate. Artemisinins seem to have multiple sites of action 
for their rapid killing effect[20]. In vitro, heme and iron 
catalyze the conversion of artemisinins to free radicals, i.e., 
the reduction of the endoperoxide bridge by an electron 
from ferrous iron (Fe2+) to a free radical and the ferrous 
ion to ferric iron (Fe3+). The free radicals will alkylate 
and oxidize proteins and lipids (but not DNA/RNA) within 
the infected red blood cells, leading to the death of the 
parasite[21]. This mechanism, likely to be a mode of action, 
is consistent to the first evidence that artemisinin activity 
is potentiated by oxidizing agents and attenuated by 
reducing agents[18]. However, this phenomenon should 
occur in the food vacuole of the parasite. In addition, other 
primary targets for artemisinin action include: (1) activation 
of mitochondrial electron transport system resulting in 
reactive oxygen species production[22,23]; (2) inhibition of 
mitochondrial oxygen utilization through cytochrome c 
oxidase complex[24]; (3) inhibition of sarcoplasmic reticulum 
calcium adenosine triphosphatase (pfatp6)[25], (which has not 
been reproduced by other studies)[4,26,27]; (4) inhibition of the 
parasite endocytosis of host protein, as studied by proteomic 
approach[4]; (5) hydroxylation of parasite biomolecules by 
generation of hydroperoxide from the artemisinin structure 
itself[28]. Studies, to date, underscore the incompletely 
understood mechanism of action for artemisinin drugs. 
3. Artemisinin chemotherapy as artemisinin-based 
combination therapy (ACT)
  In monotherapy, artemisinin acts rapidly against the 
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parasites and has faster clearance of the parasites from the 
blood than any other antimalarial drugs, resulting in faster 
relief of clinical symptoms[17,29]. However, patients must 
take the drug for at  least  7 days to maximize cure rates 
due to its very short half-life, otherwise some parasites 
could escape from the action of the drug during treatment. 
Thus, the failure to complete the whole drug treatment 
timeline, due to misleading rapid improvement in clinical 
symptoms, can lead to high levels of treatment failure[17,29]. 
An approach to circumvent this problem is to use 
combination therapy comprising of artemisinin derivatives 
plus another antimalarial drug with longer half-life and 
a different mode of action, known as artemisinin-based 
combination therapy or ACT[7].  These ACTs can be taken for 
shorter durations (<3 days) than artemisinin monotherapy, 
and importantly, can increase patient compliance thus 
reducing the risk of resistant parasites arising during 
therapy.  ACTs such as artesunate-mefloquine, artemether-
lumefantrine, artesunate-amodiaquine and artesunate-
sulfadoxine/pyrimethamine are currently in use in many 
disease endemic countries (Table 2)[5,10,17,29-31]. The first 
ACT, artesunate-mefloquine, was deployed on the northwest 
border of Thailand in 1994, an area of the mefloquine-
resistant parasites, and has retained efficacy over 14 
years[17]. The fixed-dose ACTs standard or frequently 
use dose and duration for treatment are fully described, 
including pipeline of new combinations[5,30,31]. ACTs are now 
recommended by the WHO as the first-line treatment for all 
falciparum malaria parasites in malaria endemic countries 
of the world[32].
Table 1 
Novel potential drug targets of  P. falciparum with active inhibitors presently under development and by in silico analysis[4,9,11,13-15].
Metabolic pathway Enzyme Compartment   
Nucleotide biosynthesis 
Dihydroorotate dehydrogenase, Hypoxanthine  guanine, 
Phosphoribosyltranferase,Thymidylate kinase
Mitochondria cytosol
Fatty acid synthesis Type II fatty acid synthase,  Enoyl-ACP reductase Apicoplast
Glycolysis Lactate dehydrogenase, Hexokinase Cytosol
Electron transport system Cytochrome C reductase Mitochondria
Hemoglobin catabolism Plasmepsin, Falcipain Food vacuole
Folate biosynthesis Dihydrofolate reductase,Thymidylate synthase Cytosol
Transporter Folate transporter, Hexose transporter Cell membrane
Histone acetylation Histone acetyltransferase, Histone deacetylase Nucleus
Table 2
All available pipeline of artemisinin-based combination therapy[5,10]. 
Active ingredients Partnership Product name  
Artesunate-mefloquine Far-Manguinhos, DNDi1 -
Artesunate-amodiaquine Sanofi-aventis, DNDi Coarsucam
Artesunate-pyronaridine Shin Poong, MMV2 Pyramax
Artesunate-ferroquine Sanofi-aventis Ferroquine
Artemether-lumefantrine Novartis, MMV Coartem
Dihydroartemisinin-Piperaquine  Sigma-Tau, MMV; Chongqing, Holley Eurartesim, Artekin;  Duocotexin
Artesunate-sulfadoxine/ pyrimethamine - -
1Drugs for neglected disease initiative; 2Medicine for malaria venture.
4. Evidence of artemisinin resistance/tolerance in 
human malaria  patients
  Up to now, falciparum parasite resistance to artemisinin 
and derivative drugs in human patients has not been clearly 
documented. Artemsinins have been used as monotherapy 
in the Thai-Cambodian border for over 30 years; artemisini-
based combination therapies (i.e., artesunate-mefloquine 
combination) were introduced there in 2001 as the first-
line treatment for falciparum malaria[7]. Until very recently, 
Dondorp et al reported a decrease in clinical efficacy 
of the artemisinin derivative in artesunate-mefloquine 
treatment in the falciparum malaria patients at the Thai-
Cambodian border in 2009, showing that the parasites clear 
slowly from the patients’ blood after the ACT treatment 
without corresponding reductions on in vitro susceptibility 
testing[33]. The open-label, randomized trials, compared 
the therapeutic responses to artesunate in patients with 
uncomplicated falciparum malaria in Palin province, 
western Cambodia, where reduced effectiveness has been 
reported, and Wang Pha district, western Thailand, where 
artemisinins remain highly effective since the use of this 
ACT in 1994. Forty patients from each site were treated 
in the hospital with oral artesunate at 2 mg/kg per day 
for 7 days or at 4 mg/kg per day for 3 days followed by 
mefloquine at two doses totaling 25 mg/kg per day. Using 
similar drug concentration profiles in both sites, the mean 
parasite clearance time  was 84 hours (range: 60-96 hours) 
in Cambodian patients, compared with 48 hours (range: 36-
66 hours) in Thai patients (P value=0.001). The study, thus, 
indicates that the Cambodian patients took almost twice 
as long to clear the parasite from their body as the Thai 
subjects. With artesunate monotherapy, recrudescence 
of parasite infection after more than 7 days of treatment 
initiation occurred in 30% of Cambodian patients compared 
to 19% in Thai patients, a sign of moderate resistance by 
WHO definition. Using combined therapy, parasite infection 
recurred only by about 5% in each site. The study also 
ruled out the association of clearance rates and genetic 
polymorphisms in pfcrt (chloroquine resistance transporter 
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gene), pfmdr1(multidrug resistance gene) or pfatp6 (a 
sarcoplasmic reticulum Ca2+ATPase).
  There have previous reports that provides some glimpse 
of  reducing susceptibility to artemisinins. In 2003, Yang 
et al first reported the 3.3-fold decreased susceptibility 
to artesunate during the 1988-1999 period for falciparum 
patients in Yunnan province, southwest China, an area 
where the drugs have been used for a long time[34]. The 
reduced in vitro sensitivity to artemether in field isolates 
of the falciparum malaria parasites from Cambodia, 
French Guiana and Senegal was, likewise, confirmed in 
2005 by Jambou et al[26]  Prior to Dondorp et al[33],  there 
have also been reports to reduced in vitro as well as in 
vivo susceptibility at the Thai-Cambodian border[35-39]. 
The Thai-Cambodian border is a historical epicenter for 
chloroquine, sulfadoxine-pyrimethmine resistance- and 
later multidrug-resistant falciparum parasites in the last 50 
years, including mefloquine and lumefantrine, partner drugs 
used in ACTs[17]. In Africa, recent reports have also dwelt 
with reduced susceptibility to artemisinins in response to 
falciparum parasites isolated from human patients, with 
inference on pfmdr1 amplification and the pfmrp1 mutation 
playing major roles in the decreased response of the 
parasites to these drugs[40-42].   
  Although it is still debated whether real resistance 
or tolerance to artemisinin therapy can be observed in 
human patients, the most recent work of Dondorp et 
al[33,43], supports that  “partial artemisinin resistance” 
has emerged at the Thai-Cambodian border, which is 
characterized by much slower parasite clearance rate 
under the drug pressure. Three major driving forces in this 
resistance phenomenon is probably due to: (1) artemisinin 
monotherapy; (2) subtherapeutic doses of artemisinin; (3) 
substandard and counterfeit artemisinins[43]. Although, using 
the delayed clearance of the parasites as an indicator may 
not be sufficient to monitor the patients ability to reduce 
efficacy of the drug during the duration of treatment;  there 
have been limitations on the candidate markers used (thus 
reflecting our incomplete understanding in the mechanism 
of action) and the lack of standardized cutoff  IC50 values. 
The indicators currently used to dissect this phenomenon 
are molecular markers pfmdr1, pfcrt, pfatp6, pfmrp1, etc.  in 
vitro IC50s, and  in vivo clearance rate. 
5. Mechanism of artemisinin resistance/tolerance and 
molecular markers
  The delayed clearance suggests that some parasites can 
survive the drug treatment for a longer period of time than 
expected, but they are eventually killed by the drug. This 
phenomenon is not due to human host and other factors 
related to the human population in this region. It can 
be explained solely from parasite genetics, as measured 
heritability of the clearance rate in patients infected with 
identical or nonidentical parasite genotypes, suggesting the 
selection with artemisinin will drive the drug resistance 
spread[44]. It is interesting that candidate genes responsible 
for the parasite clearance rate  and the drug resistance 
remain to be identified.
  In 2007, in vitro selection of the falciparum parasites with 
decreased susceptibility to artesunate by a factor of 5 to 10 
was found to be genetically unstable for the drug-response 
phenotype. The drug resistant parasites obtained did not 
correlate with ubp-1 mutation[45]. The upb-1 gene encodes 
the P. falciparum othrologue of the deubiquitinating 
enzyme, responsible for proteasome-degradation pathway. 
Most recently, long-term artemisinin pressure to the in vitro 
falciparum parasite (over a period of 3 years) produced the 
artemisinin tolerant parasite that can survive extremely high 
doses of the drug, i.e., up to 7 000-fold of the initial IC50. 
The parasite development was arrested at the ring stage, as 
dormant form, when it was under high doses of artemisinin 
pressure, but resumed its regular intraerythrocytic cycle 
after drug removal. During the acquisition of artemisinin 
tolerance, the parasite overexpressed heat shock and 
erythrocyte surface proteins and down-expressed a cell 
cycle regulator and a DNA biosynthesis protein, suggesting a 
new and quiescence response mechanism of drug tolerance 
in P. falciparum[46]. 
  In vitro induction of the falciparum malaria parasite 
resistance to artemisinins by other investigators showed 
that the resistant parasite has decreasing susceptibility 
to mefloquine, quinine, halofantrine and lumefantrine, in 
addition to artemisinin[47]. Furthermore, the parasite  has 
increased pfmdr1 gene copy number, mRNA and protein 
expression, but it had no mutation of the pfmdr1 and pfatp6 
genes.  This study suggests that the in vitro artemisinin 
resistance can be developed and the mechanism of the 
resistance likely involves amplification and increased 
expression of the pfmdr1 gene, which is the same mechanism 
for mefloquine resistance. In contrary, the phenomenon 
on gene amplification and expression is, however, not 
observed in the parasites from in vivo or the human patient 
tolerant to artemisinin treatment[33,48],  which in turn has 
been explained by the de-amplification (i.e., instability) 
mechanism of pfmdr1 gene amplicon, covering 19 genes 
when the drug pressure is withdrawn[49]. The phenotype of 
artemisinin-resistant parasites in human patients are not 
linked to at least five candidate genes to be known, i.e., 
pfmdr1, pfatp6, ubp-1, pfcrt and the 6-kb mitochrondrial 
genome[48].
  The pfmdr1 gene copy number was increased three or more 
copies in the parasites associated with recrudescence in 
the artesunate-mefloquine treated patients[38]. The pfmdr1 
is likely to be used as a molecular marker of the combined 
drug treatment failure in falciparum malaria on the Thai-
Cambodian border. Whereas, in African patients, the pfmrp1 
mutation is found to involve in vivo response of the parasites 
to the drugs. The pfmrp1, encoded by pfmr1 gene, is an 
1822-amino acid protein situated in the parasite plasma 
membrane, which plays a role in parasite drug sensitivity 
through efflux of drugs[41].   
  Having used transcriptome analysis in the falciparum 
parasite exposed in vitro to short time lethal doses of 
artesunate, sensitive pathways such as purine/pyrimidine 
metabolism, mitochondria electron transport system, protein 
degradation (through ubiquitin-dependent pathway) and the 
food vacuole integrity were identified[50]. The transcriptome 
and proteomic approach offers benefit for candidate 
markers identification for the emergence of artemisinin 
resistance[4,50].
6. WHO malaria containment program 
  With the development of resistance to front-line drug, 
and no new treatments in the pipeline, there is a growing 
concern for the potential of artemisinin resistance to develop 
in the falciparum malaria parasite. An urgent campaign 
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coordinated by the WHO has been launched to contain the 
artemisinin resistance in the Thai-Cambodian border[51]. 
The control program involves rapid diagnosis and effective 
treatment, reduction of drug pressure, vector control 
optimization, target on human movement/mobilization, 
strengthening of management and surveillance systems, and 
operational research. Details of the program in all issues 
identified above are found in the WHO report 2008[51], and 
highlighted by Dondorp et al in 2010[43].
7. Concluding remarks and future prospects
  Currently, ACTs are the best weapon against malaria. 
However, lines of evidence have been accumulating very 
recently that the P. falciparum parasites on the Thai-
Cambodian border are less effective to ACTs after 10 years 
of the drug therapy. This is due to the emergence of the 
malaria parasites that are partially resistant/tolerant to 
artemisinin derivatives, exhibiting by a clearance delay. The 
delay in parasite clearance is associated with an increased 
risk of gametocytemia, therefore, presumably with a 
potential for increased transmissibility of the drug resistant 
parasites[52]. Although the drugs have broad stage specificity 
of antimalarial action, its mechanism of action remains 
to be verified. This includes Fe-dependent alkylation of 
the parasite proteins, mitochondrial electron transport 
system and oxygen utilization. A better understanding of 
the mechanism of action is urgent. It is critical at the first 
step to elucidate the mechanism of artemisinin resistance 
and identify molecular markers/measurements that can be 
used as tools for monitoring the appearance and spread of 
resistance. Identification of molecular targets/mechanism of 
the resistance may require vigorous efforts in  transcriptome 
and proteomic analysis or high-throughput methods for 
gene mapping, such as, single nucleotide polymorphisms 
and microsatellites[50,53]. Indeed, factors contributing to the 
artemisinin resistance phenomenon may be multifactorial 
causes[52].
  At present, it is fortunate that no strong evidence of 
artemisinins resistance occurs anywhere else in the world or 
nearby the Thai-Burmese border[54], and the Vietnamese-
Cambodian border[55], however, artemisinin efficacy has 
declined in many endemic countries worldwide. The 
strongest evidence supporting the partial drug resistance 
appears to be isolated at the Thai-Cambodian border; and 
the WHO has, therefore, launched programs for prevention 
or containment of the artemisinin resistant malaria. Finally, 
the increasing malaria morbidity and mortality in endemic 
countries around the world vis a vis malaria eradication is 
an ongoing battle, with very urgent needs to develop new 
antimalarial drugs to fight against this disease, leading to 
effective global malaria control programs for our malaria-
free world[56].
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